RIVM launches study on long-term effectiveness of COVID-19 vaccines RIVM is launching an extensive study today to research the long-term effectiveness of the various COVID-19 vaccines in the Netherlands.
RIVM researchers win best paper award of the journal Risk Analysis RIVM researchers Arie Havelaar and Arno Swart received the prestigious Best Paper Award 2014 of the Society for Risk Analysis.